SARS-2- CoV Variants and Therapuetic Responses

Abstract

Background: The continued circulation and adaptive evolution of SARS-CoV-2 represents one of the most formidable challenges in contemporary infectious disease medicine. The virus has been demonstrated as a remarkable capacity for generating consecutive waves of variants that outdo immune defences and reduce the effectiveness of previously established therapeutic procedures Objective: The current evidence on variant-specific genetic changes, their phenotypic consequences, and their corresponding evolution of pharmacological interventions from direct-acting antivirals to host-directed immunomodulatory and next-generation broadly neutralizing antibodies. Methods: A systematic review was conducted, WHO epidemiological bulletins, and clinical trial registries was conducted. Studies addressing VOC genomics, clinical outcomes, therapeutic efficacy, and public health implications were included. Results: Five major VOCs Alpha, Beta, Gamma, Delta, and Omicron—have each reshaped the pandemic landscape through distinct spike protein alterations, with Omicron's 30+ mutations conferring unprecedented immune evasion. Antiviral agents such as nirmatrelvir/ritonavir and remdesivir retain activity across most variants, while several monoclonal antibodies have lost neutralizing potency. Immunomodulatory regimens incorporating dexamethasone and IL-6 inhibitors remain the cornerstone of severe disease management. Conclusion: Addressing SARS-CoV-2 as an evolving endemic pathogen requires adaptive therapeutic frameworks, investment in pan-coronavirus drug targets, and global strategies to close equity gaps in access to diagnostics and treatment.